Idoxuridine
Dendrid, Herplex, Stoxil (idoxuridine) is a small molecule pharmaceutical. Idoxuridine was first approved as Dendrid on 1982-01-01. It is used to treat dendritic keratitis and virus diseases in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| eye diseases | D005128 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| elaprase | Biologic Licensing Application | 2025-04-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| virus diseases | — | D014777 | B34 |
| dendritic keratitis | EFO_1001883 | D007635 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BB: Antivirals, topical
— D06BB01: Idoxuridine
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AB: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
— J05AB02: Idoxuridine
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AD: Antivirals, ophthalmologic
— S01AD01: Idoxuridine
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | — | — | — | 1 | 4 | 5 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | — | — | 2 | — | 2 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | — | 2 | — | 2 |
| Neurogenic urinary bladder | D001750 | HP_0000011 | N31 | — | — | — | 1 | — | 1 |
| Urge urinary incontinence | D053202 | EFO_0006865 | N39.41 | — | — | — | 1 | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | 1 | — | 1 |
| Multiple system atrophy | D019578 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | 4 | 5 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | 1 | — | — | 1 |
| Headache | D006261 | — | R51 | — | — | 1 | — | — | 1 |
| Temporomandibular joint disorders | D013705 | — | M26.6 | — | — | 1 | — | — | 1 |
| Facial pain | D005157 | — | R51.9 | — | — | 1 | — | — | 1 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | — | — | 1 | — | — | 1 |
| Acrodynia | D000170 | EFO_1001756 | — | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | 1 | 1 | — | — | — | 2 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 1 | — | — | — | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 1 | — | — | — | 1 |
| Cluster headache | D003027 | — | G44.00 | 1 | 1 | — | — | — | 1 |
| Ganglion cysts | D045888 | — | M67.4 | 1 | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | — | 1 | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | 1 | — | — | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 1 | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | — | 1 |
| Bile duct neoplasms | D001650 | — | — | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv | D006678 | — | O98.7 | — | — | — | — | 5 | 5 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 3 | 3 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 3 | 3 |
| Hepatitis | D006505 | — | K75.9 | — | — | — | — | 3 | 3 |
| Hiv seropositivity | D006679 | — | — | — | — | — | — | 2 | 2 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | — | 2 | 2 |
| Drug misuse | D000076064 | — | — | — | — | — | — | 1 | 1 |
| Coinfection | D060085 | — | — | — | — | — | — | 1 | 1 |
| Hepatitis b | D006509 | — | — | — | — | — | — | 1 | 1 |
| Intravenous substance abuse | D015819 | — | — | — | — | — | — | 1 | 1 |
Show 7 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Idoxuridine |
| INN | idoxuridine |
| Description | 5-iodo-2'-deoxyuridine is a pyrimidine 2'-deoxyribonucleoside compound having 5-iodouracil as the nucleobase; used as an antiviral agent. It has a role as an antiviral drug and a DNA synthesis inhibitor. It is a pyrimidine 2'-deoxyribonucleoside and an organoiodine compound. |
| Classification | Small molecule |
| Drug class | antivirals; antineoplastics (uridine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I |
Identifiers
| PDB | — |
| CAS-ID | 54-42-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL788 |
| ChEBI ID | 147675 |
| PubChem CID | 5905 |
| DrugBank | DB03778 |
| UNII ID | LGP81V5245 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,503 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elaprase
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,961 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use